In this episode of Conversations in healthcare, Mike Ward, Global Head of Thought Leadership talks to Dana Gheorghe, Ph.D, Associate Director, Oncology, about the impact COVID-19 is having on treatment for already available CAR T-cell therapies as well as those being developed. Dana gives us the lay of the land in an area where there is scarcity of information that is frequently changing. Dana covers how patients are being prioritised according to risk and need at this time and the challenges of getting high risk patient profiles much needed treatments. She also discusses the various country and region-specific conditions that are being put in place to allow treatment and trials to continue, however, many existing trials and read outs have been delayed despite and new trials completely suspended. Hosted on Acast. See acast.com/privacy for more information.